Prosecution Insights
Last updated: May 29, 2026

Examiner: GONZALEZ, LUISALBERTO

Tech Center 1600 • Art Units: 1624

This examiner grants 61% of resolved cases

Performance Statistics

61.4%
Allow Rate
+1.4% vs TC avg
196
Total Applications
+47.4%
Interview Lift
1045
Avg Prosecution Days
Based on 140 resolved cases, 2023–2026

Rejection Statute Breakdown

1.1%
§101 Eligibility
5.1%
§102 Novelty
49.2%
§103 Obviousness
18.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18567504 ISOQUINOLINE AND PYRIDINE BASED CXCR4 ANTAGONISTS Non-Final OA Katholieke Universiteit Leuven
18934169 COMPOUNDS AND METHODS FOR USING GALLOYLATED POLYPHENOLS TO TREAT DISEASES MEDIATED BY THIOL ISOMERASES Non-Final OA Beth Israel Deaconess Medical Center, Inc.
18556635 Compositions comprising resinous exudate metabolites from plants of the genus Adesmia, used to control and treat infections in plant crops; and methods for controlling infections in plant crops. Non-Final OA UNIVERSIDAD TÉCNICA FEDERICO SANTA MARÍA
18667063 CANNABINOID, DRUG ADDICTION TREATMENT AND MENTHOL COMPOSITIONS AND METHODS Final Rejection 7X Enterprises, LLC
18581095 Halogenated Xanthenes as Vaccine Adjuvants Final Rejection UTI Limited Partnership
18551942 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS Non-Final OA CHIESI FARMACEUTICI S.p.A.
18628470 FORMULATIONS OF KINASE INHIBITORS AND PROSTANOIDS Non-Final OA PULMOKINE, INC.
18600654 Topical Antimicrobial Lotion for Treating Pyotraumatic Dermatitis Lesions Final Rejection Shear Kershman Laboratories, Inc.
18103193 Canine Melatonin-Containing Transmucosal Gel Non-Final OA Shear Kershman Laboratories, Inc.
18575454 NEW METHOD TO TREAT ACIDOSIS RELATED DISEASES WITH ACETOACETATE Non-Final OA CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS
18575414 CRYSTALLINE FORMS OF 3-{4-[(2R)-2-AMINOPROPOXY]PHENYL}-N-[(1R)- 1-(3-FLUOROPHENYL) ETHYL]IMIDAZO[1,2-B]PYRIDAZIN-6-AMINE AND SALTS THEREOF Non-Final OA Nuvation Bio Inc,
18567396 SOLID STATE FORMS OF ABEXINOSTAT AND PROCESS FOR PREPARATION THEREOF Non-Final OA ASSIA CHEMICAL INDUSTRIES LTD.
18038506 PROCESSES FOR THE PREPARATION OF ZANUBRUTINIB AND INTERMEDIATES THEREOF Non-Final OA ASSIA CHEMICAL INDUSTRIES LTD.
18528113 COMPOSITIONS, FORMULATIONS, AND METHODS FOR HAIR TREATMENT Non-Final OA Oddity Labs, LLC
17439668 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA Non-Final OA ATROGI AB
18564553 METHODS OF TREATING SUBSTANCE USE DISORDERS USING MESCALINE Non-Final OA Journey Colab Corp.
18518796 METHOD FOR PREPARING ACESULFAME POTASSIUM Non-Final OA ANHUI JIHNE INDUSTRIAL CO., LTD.
18258455 1,8-CINEOLE CONTAINING COMPOSITION FOR THERAPEUTIC USE Non-Final OA Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH
18202051 COMPOSITIONS FOR A DIETARY SUPPLEMENT TO MANAGE SENESCENT CELLS Non-Final OA Qualia Life Sciences LLC
18038090 BIOCIDE Non-Final OA PURGOS APS
18252688 RAPIDLY DISINTERGRATING COMPOSITIONS AND METHODS (Nicotine) Non-Final OA ORCOSA INC.
18252067 SOLID DISPERSIONS OF CANNABIDIOL Final Rejection INDENA S.P.A.
18033292 FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME Non-Final OA GenEros Biopharma Ltd.
18022081 TOPICAL CANNABINOID COMPOSITIONS, ANTI-INFLAMMATORY CANNABINOID COMPOSITIONS, METHODS FOR FORMING, AND METHODS FOR TREATMENT Non-Final OA AGRONOMED MANAGEMENT, LLC
18000586 METHODS AND COMPOSITIONS FOR TREATMENT OF HEAD LICE Non-Final OA CReDO Science, LLC
17359714 MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE Final Rejection IMBRIA PHARMACEUTICALS, INC.
17860539 THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM Non-Final OA HARMONY BIOSCIENCES, LLC
17772452 Cannabinoid Products with High Bioavailability Final Rejection The Chemist's Cabinet, LLC
17593792 TOPICAL FORMULATIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES Final Rejection WinSanTor, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month